Clinical trial · Observational
Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer
Urine Prostaglandin-M(PGE-M) in Ovarian Cancer
NCT00900523CI-TRIAL-00010083completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to ovarian cancer and may help the study of cancer in the future. PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunohistochemistry | Other | — | UNRESOLVED |
| protein expression analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Known or suspected ovarian cancer
- description
- Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
- interventionNames
- Genetic: protein expression analysis
- Other: immunohistochemistry
Primary outcomes (1)
- measure
- Prostaglandin E2 metabolite (PGE-M) levels in 24-hour urine samples
- timeFrame
- Pre-surgical or chemotherapeutic treatment, over a 24-hour duration
- description
- Patients will be collect their urine for 24 hours before they undergo any surgery or chemotherapy. Researchers will measure the amount of PGE-M in the urine.
Secondary outcomes (2)
- measure
- COX-1 and COX-2 expression in ovarian tumor tissue and non-malignant tissue
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of known or suspected ovarian cancer * Age greater than 17 years Exclusion Criteria: * Pregnant or nursing * Taking steroids or non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis. PRIOR CONCURRENT THERAPY: * No concurrent chronic use of steroids or NSAIDs
References
Publications (0)
Data not yet available
No reference posted for this study.